Development and characterization of naproxen-chitosan solid systems with improved drug dissolution properties

被引:75
作者
Mura, P
Zerrouk, N
Mennini, N
Maestrelli, F
Chemtob, C
机构
[1] Univ Florence, Fac Farm, Dipartimento Sci Farmaceut, I-50121 Florence, Italy
[2] Univ Paris 05, Fac Sci Pharmaceut & Biol, Pharm Galen Lab, F-75270 Paris 06, France
关键词
naproxen; chitosan; dissolution enhancement; cogrinding; differential scanning calorimetry;
D O I
10.1016/S0928-0987(03)00068-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The solubilizing and amorphizing properties toward naproxen (a poorly water-soluble antiinflammatory drug) of chitosan, an emerging pharmaceutical biopolymer, have been investigated. Solid binary systems at different drug/polymer ratios have been prepared according to different techniques (mixing, cogrinding, kneading, coevaporation) using chitosan at low (CS-L-w) and medium (CS-M-w) molecular weight, and tested for dissolution properties. Drug-carrier interactions were investigated in both the liquid and solid state, by phase solubility analysis, differential scanning calorimetry, X-ray powder diffractometry, FT-IR spectroscopy, and scanning electron microscopy. Drug dissolution parameters improved with increasing the polymer amount in the mixture, reaching the highest values at the 1:9 (w/w) drug/polymer ratio, and CS-L-w was more efficacious than CS-M-w. Cogrinding was the most effective technique, showing the strongest amorphizing effect toward the drug and enabling an increase of more than ten times its relative dissolution rate. Coground mixtures at 3:7 (w/w) drug/polymer ratio were able to give directly compressed tablets which maintained unchanged the improved drug dissolution properties. Enhancer dissolution properties combined with its direct compression feasibility and antiulcerogenic action make CS-L-w an optimal carrier for developing fast-release oral solid dosage forms of naproxen. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:67 / 75
页数:9
相关论文
共 30 条
[1]  
ACARTURK F, 1993, PHARMAZIE, V48, P605
[2]  
ACARTURK F, 1993, STP PHARMA SCI, V3, P369
[3]  
ACIKGOZ M, 1995, PHARMAZIE, V50, P275
[4]   EFFECT OF CHITOSAN ON THE PERMEABILITY OF MONOLAYERS OF INTESTINAL EPITHELIAL-CELLS (CACO-2) [J].
ARTURSSON, P ;
LINDMARK, T ;
DAVIS, SS ;
ILLUM, L .
PHARMACEUTICAL RESEARCH, 1994, 11 (09) :1358-1361
[5]   DISSOLUTION PROPERTIES OF NAPROXEN IN COMBINATIONS WITH POLYVINYLPYRROLIDONE [J].
BETTINETTI, G ;
MURA, P .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1994, 20 (08) :1353-1366
[6]  
BETTINETTI GP, 1989, FARMACO, V44, P195
[7]   PHARMACEUTICAL APPLICATIONS OF SOLID DISPERSION SYSTEMS - X-RAY-DIFFRACTION AND AQUEOUS SOLUBILITY STUDIES ON GRISEOFULVIN-POLYETHYLENE GLYCOL 6000 SYSTEMS [J].
CHIOU, WL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1977, 66 (07) :989-991
[8]   Chitosan: A unique polysaccharide for drug delivery [J].
Felt, O ;
Buri, P ;
Gurny, R .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1998, 24 (11) :979-993
[9]   Bioadhesion of hydrated chitosans: An in vitro and in vivo study [J].
Henriksen, I ;
Green, KL ;
Smart, JD ;
Smistad, G ;
Karlsen, J .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 145 (1-2) :231-240
[10]  
Higuchi T., 1965, Interscience, New York, V4, P117